LILRB3 was up-regulated in a variety of cancers, including AML (Fig. 1A) [7, 19, 20], and was significantly increased in AML patients compared to normal people, based on GEPIA data (Fig. 1B). Here, LILRB3 is linked to acute myeloid leukemia.